Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?

This agreement will see Kadimastem acquired by a wholly-owned subsidiary of NLS Pharmaceutics. When that happens, Kadimastem investors will obtain 85% of NLSP stock. This will see the combined company operate under the Kadimastem name. That will leave the remaining 15% for NLSP investors. Alex Zwyer, CEO of NLS Pharmaceutics, said the following about the merger. The two companies expect to execute the agreement in September. This should see the deal close by the end of the year. NLSP stock is seeing heavy t ...